On­coMed chief Paul Hast­ings goes on med­ical leave

The long­time biotech ex­ec and On­coMed $OMED CEO Paul Hast­ings is go­ing on med­ical leave.

There’s no im­me­di­ate word about what ails him, but the biotech says that Hast­ings will keep his ti­tles as he re­mains on med­ical leave at the biotech, which is fo­cused on new can­cer ther­a­pies.

In the mean­time, the com­pa­ny will be led by a se­nior man­age­ment team with an “Of­fice of the Pres­i­dent” con­sist­ing of R&D chief John Lewic­ki and CFO Sunil Pa­tel.  In ad­di­tion, On­coMed’s board has ap­point­ed a spe­cial com­mit­tee con­sist­ing of Jack Laser­sohn, the lead di­rec­tor, with Per­ry Karsen, Deepa Pakianathan and Rick Win­ning­ham to work close­ly with Lewic­ki and Pa­tel dur­ing Hast­ings’ leave.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER